1219 related articles for article (PubMed ID: 12442345)
21. Emerging role of aromatase inhibitors in the adjuvant setting.
Goss PE
Am J Clin Oncol; 2003 Aug; 26(4):S27-33. PubMed ID: 12902874
[TBL] [Abstract][Full Text] [Related]
22. Letrozole : in postmenopausal hormone-responsive early-stage breast cancer.
Scott LJ; Keam SJ
Drugs; 2006; 66(3):353-62. PubMed ID: 16526826
[TBL] [Abstract][Full Text] [Related]
23. Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?
Howell A; Howell SJ; Clarke R; Anderson E
J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):227-37. PubMed ID: 11850229
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant comparisons of aromatase inhibitors and tamoxifen: pretreatment determinants of response and on-treatment effect.
Ellis MJ; Rosen E; Dressman H; Marks J
J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):301-7. PubMed ID: 14623525
[TBL] [Abstract][Full Text] [Related]
25. A decade of letrozole: FACE.
O'Shaughnessy J
Breast Cancer Res Treat; 2007; 105 Suppl 1(Suppl 1):67-74. PubMed ID: 17912637
[TBL] [Abstract][Full Text] [Related]
26. [Letrozole vs. placebo after adjuvant tamoxifen in postmenopausal breast cancer: the MA-17 study].
Gori S; Anastasi P; Marrocolo F
Suppl Tumori; 2004; 3(4):S27-31. PubMed ID: 15206206
[No Abstract] [Full Text] [Related]
27. [Letrozole vs. placebo after adjuvant tamoxifen in postmenopausal breast cancer. The example of the MA-17 study].
Forciniti S
Suppl Tumori; 2004; 3(4):S25-6. PubMed ID: 15206205
[No Abstract] [Full Text] [Related]
28. Emerging role of aromatase inhibitors in the treatment of breast cancer.
Harvey HA
Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):32-5. PubMed ID: 9556789
[TBL] [Abstract][Full Text] [Related]
29. Letrozole as adjuvant endocrine therapy in postmenopausal women with breast cancer.
Koeberle D; Thuerlimann B
Expert Rev Anticancer Ther; 2006 Jan; 6(1):5-10. PubMed ID: 16375638
[TBL] [Abstract][Full Text] [Related]
30. Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes.
Dixon JM; Jackson J; Renshaw L; Miller WR
J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):295-9. PubMed ID: 14623524
[TBL] [Abstract][Full Text] [Related]
31. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.
Ellis MJ; Coop A; Singh B; Mauriac L; Llombert-Cussac A; Jänicke F; Miller WR; Evans DB; Dugan M; Brady C; Quebe-Fehling E; Borgs M
J Clin Oncol; 2001 Sep; 19(18):3808-16. PubMed ID: 11559718
[TBL] [Abstract][Full Text] [Related]
32. The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer.
Hamilton A; Piccart M
Ann Oncol; 1999 Apr; 10(4):377-84. PubMed ID: 10370778
[TBL] [Abstract][Full Text] [Related]
33. The impact of hormone receptor status on the clinical efficacy of the new-generation aromatase inhibitors: a review of data from first-line metastatic disease trials in postmenopausal women.
Buzdar AU; Vergote I; Sainsbury R
Breast J; 2004; 10(3):211-7. PubMed ID: 15125747
[TBL] [Abstract][Full Text] [Related]
34. Use of aromatase inhibitors in postmenopausal women with advanced breast cancer.
Roseman BJ; Buzdar AU; Singletary SE
J Surg Oncol; 1997 Nov; 66(3):215-20. PubMed ID: 9369969
[TBL] [Abstract][Full Text] [Related]
35. Letrozole for the management of breast cancer.
Goss PE; Smith RE
Expert Rev Anticancer Ther; 2002 Jun; 2(3):249-60. PubMed ID: 12113048
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Méry E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thürlimann B; Coates AS; Viale G;
Lancet Oncol; 2008 Jan; 9(1):23-8. PubMed ID: 18083065
[TBL] [Abstract][Full Text] [Related]
37. Should aromatase inhibitors replace tamoxifen?
Drug Ther Bull; 2003 Aug; 41(8):57-9. PubMed ID: 12966738
[TBL] [Abstract][Full Text] [Related]
38. Biology of aromatase inhibitors: pharmacology/endocrinology within the breast.
Miller WR
Endocr Relat Cancer; 1999 Jun; 6(2):187-95. PubMed ID: 10731108
[TBL] [Abstract][Full Text] [Related]
39. Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer.
Brodie A; Lu Q; Liu Y; Long B; Wang JP; Yue W
Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):36-40. PubMed ID: 9556790
[TBL] [Abstract][Full Text] [Related]
40. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
